U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07365995) titled 'A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer' on Jan. 23.
Brief Summary: This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicines prednisone or prednisolone). The study will include participants with mCRPC that have been previously treated with androgen receptor pathway inhibitor, but with no previous taxane-based systematic chemotherapy for mCRPC.
The main goals of this study are:
* To find out if B...